Improving risk assessment for pancreatic cancer using genetic information
Official title: Multifactor risk scores with susceptibility gene mutations to enhance risk assessment of pancreatic cancer
Funded at Mayo Clinic Rochester · NIH-10931357 · Data updated 2026-11-12
This study is looking to create a new way to figure out who might be at higher risk for pancreatic cancer by using genetic information, especially for family members of people who have had the disease, so they can get more personalized care and possibly catch any issues earlier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $142,096 |
| NIH project number | 5R01CA272668-02 |
| Project ID | NIH-10931357 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of pancreatic cancer, particularly first-degree relatives of affected patients.
✕Less likely to help
Patients without a family history of pancreatic cancer or those not carrying hereditary cancer syndrome mutations may not benefit from this research.
What this research studies
This research aims to enhance the assessment of pancreatic ductal adenocarcinoma (PDAC) risk by developing a new multifactor risk score that incorporates genetic mutations associated with hereditary cancer syndromes. By analyzing large datasets from the Mayo Clinic and the UK Biobank, the study will evaluate how these genetic factors can better identify individuals at moderate to high risk for PDAC. The approach includes using whole exome sequencing data to refine risk stratification, particularly for first-degree relatives of PDAC patients. This could lead to more personalized risk assessments and potentially earlier interventions for those at risk.
Why it matters
Potential benefit: If successful, this research could lead to improved early detection and prevention strategies for pancreatic cancer, ultimately saving lives.
How similar studies have gone: Other research has shown promise in using genetic information to enhance cancer risk assessment, indicating that this approach could be effective.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Oberg, Ann Laura — Mayo Clinic Rochester
- Study coordinator: Oberg, Ann Laura
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.